(Q33267207)
Statements
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer (English)
R Collins
R Riemsma
E Fenwick
R Trowman
R Perard
K Light
iii-iv, xv-xviii, 1-179